Axa’s Black Diamond Therapeutics BDTX Stock Holding History

Axa’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-265,580	Closed	-$6.44M	–	1254
2021 Q1	$6.44M	Buy	+265,580	New	+$7.16M	0.02%	640

Other funds holding BDTX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Axa's BDTX Position: Q2 2021 in Review

Axa sold out of Black Diamond Therapeutics (BDTX) in Q2 2021, closing a stake of 265,580 shares — an estimated $6.44M sold.

Axa first reported a position in BDTX in Q1 2021 and held it in 1 quarter. The position peaked at $6.44M in Q1 2021. 102 funds tracked by Wall St. Rank hold BDTX as of Q2 2021.

Axa reported no remaining Black Diamond Therapeutics position as of Q2 2021 after selling out during the quarter.
Axa sold 265,580 Black Diamond Therapeutics shares in Q2 2021, an estimated $6.44M.
Axa first reported a position in Black Diamond Therapeutics in Q1 2021 and held it in 1 quarter.
Axa's Black Diamond Therapeutics position peaked at $6.44M in Q1 2021.
102 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2021.

Based on Axa's 13F filing for Q2 2021, filed 13 Aug 2021.